top of page
Skin cancers
BREAK-3 trial | 2011 | Melanoma - BRAF+ |
BRIM-3 trial | 2011 | Melanoma - BRAF+ |
coBRIM trial | 2014 | Melanoma - BRAF+ |
COMBI-v trial | 2015 | Melanoma - BRAF+ |
COMBI-d trial | 2017 | Melanoma - BRAF+ |
IMspire 150 trial | 2020 | Melanoma - BRAF+ |
HD-IL-2 meta-analysis | 1999 | Melanoma - metastatic |
MDX-020-010 trial | 2010 | Melanoma - metastatic |
SEER-metastasectomy analysis | 2011 | Melanoma - metastatic |
CheckMate 069 trial, ipi/nivo vs ipi | 2015 | Melanoma - metastatic |
CheckMate 037 trial | 2015 | Melanoma - metastatic |
KEYNOTE-029 trial, pembro vs low ipi | 2017 | Melanoma - metastatic |
KEYNOTE-006 trial | 2017 | Melanoma - metastatic |
CheckMate 511 trial | 2019 | Melanoma - metastatic |
CheckMate 067 trial | 2019 | Melanoma - metastatic |
CheckMate 066 trial | 2020 | Melanoma - metastatic |
IMMUNED trial | 2020 | Melanoma - metastatic |
Tebentafusp in Metastatic Uveal Melanoma | 2022 | Melanoma - metastatic |
E-1684 trial | 1996 | Melanoma - stage III |
EORTC 18071 trial | 2016 | Melanoma - stage III |
MSLT-II trial | 2017 | Melanoma - stage III |
DeCOG-SLT trial | 2019 | Melanoma - stage III |
KEYNOTE-054 Trial/EORTC-1325 | 2020 | Melanoma - stage III |
COMBI-AD trial | 2020 | Melanoma - stage III |
CheckMate 238 trial | 2020 | Melanoma - stage III |
E1609 trial | 2020 | Melanoma - stage III |
BREAK-3 trial
Chapman PB et al, NEJM, 2011; PMID:21639808
Melanoma - BRAF+
Background: phase III RCT included 675 treatment naïve BRAF V600E+ patients with metastatic melanoma
Arm A: vemurafenib 960mg BID
Arm B: dacarbazine 1000mg/m2 IV q3wk
Primary end point: OS and PFS.
Interim analysis at 6mo demonstrated 74% reduction in progression and 63% relative reduction in death with vemurafenib (P=<.001) therefore crossover from dacarbazine to vemurafenib was recommended.
Conclusions: vemurafenib improved OS and PFS comparing to dacarbazine.
Summarized by Veli Bakalov, MD
bottom of page